Immuno-Oncology Resource Center
Immuno-Oncology Resource Center
June 09, 2020
1 min read
Save

FDA grants fast track designation to vaccine-enhanced cell therapy for glioblastoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted fast track designation to TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme, according to the agent’s manufacturer.

TVI-Brain-1 (TVAX Biomedical) is an autologous, vaccine-enhanced adoptive T-cell therapy comprising a proprietary vaccine pretreatment to generate cancer-specific T cells and an activated antitumor T-cell treatment.

Photo of brain mri
The FDA granted fast track designation to TVI-Brain-1, an adoptive T cell therapy for the treatment of glioblastoma multiforme.

The FDA's fast track designation helps to expedite development, review and potential approval of treatments for serious or life-threatening diseases.

“We are very pleased to receive fast track designation by the FDA for glioblastoma multiforme,” Wayne Carter, DVM, PhD, CEO of TVAX Biomedical, said in a company-issued press release. “Glioblastoma is a terrible disease for which there are limited clinical options.”

The FDA based the fast track designation on results of phase 1 and phase 2 studies of TVAX immunotherapy, which has demonstrated significantly increased median survival compared with historical controls, according to the manufacturer.

TVAX plans to start enrollment later this year for a phase 2b study among patients with newly diagnosed glioblastoma multiforme, according to the press release.